Patent · US Active

Compositions and methods for diagnosing Lyme disease and for predicting Lyme disease spirochete elimination after treatment

US10983121B2 · kind B2 · utility

1Cited by
3References
18Claims
0Family size

Assignees

Inventors

Key dates

Filing dateSep 15, 2016
Grant dateApr 20, 2021
Priority date
Expiry dateSep 15, 2036

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY02A50/30
  • WIPO fieldMeasurement
  • WIPO sectorInstruments

Abstract

Compositions and methods are provided for detection, diagnosis and prognosis of Lyme disease (LD), including a method for confirming Borrelia spp. infection by contacting, in vitro, whole blood samples from subjects suspected of having LD with synthetic peptides comprising T-cell epitope-containing regions derived from Borrelia proteins that are expressed at different stages of Lyme disease, and indirectly detecting LD-specific activated T-cells by determining production of a T-cell immune response indicator (e.g., interferon-Y) in response to stimulation by the peptides. Also disclosed are methods for predicting elimination of LD spirochetes in LD patients who have undergone LD treatment, by exposing whole blood samples from such subjects to peptides comprising specific T-cell epitope regions of Borrelia proteins that are expressed at different stages of Lyme disease, and confirming a lack of Borrelia-specific activated T-cells in the samples by the absence of a detectable T-cell immune response indicator (e.g., interferon-Y).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.